Exact Mass: 383.169242

Exact Mass Matches: 383.169242

Found 104 metabolites which its exact mass value is equals to given mass value 383.169242, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Prazosin

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine

C19H21N5O4 (383.15934660000005)


Prazosin is a selective α-1-adrenergic receptor antagonist used to treat hypertension. It has also been used to decrease urinary obstruction and relieve symptoms associated with symptomatic benign prostatic hyperplasia. α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. Prazosin has also been used in conjunction with cardiac glycosides and diuretics in the management of severe congestive heart failure. It has also been used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma. C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents KEIO_ID P191; [MS2] KO009165 Corona-virus KEIO_ID P191 Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder. It is an alpha-adrenergic blocker that is specific for the alpha-1 receptors. These receptors are found on vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine. They are also found throughout the central nervous system. As of 2013, prazosin is off-patent in the US, and the FDA has approved at least one generic manufacturer.In addition to its alpha-blocking activity, prazosin is an antagonist of the MT3 receptor (which is not present in humans), with selectivity for this receptor over the MT1 and MT2 receptors. Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. However, when prazosin is initially started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases.

   

Quetiapine

2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol

C21H25N3O2S (383.166739)


The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; Quetiapine belongs to a series of neuroleptics known as "atypical antipsychotics", which have become increasingly popular alternatives to "typical antipsychotics" such as haloperidol. Quetiapine HAS approvals for the treatment of schizophrenia and acute mania in bipolar disorder. It is also used off-label to treat other disorders, such as post-traumatic stress disorder, alcoholism, obsessive compulsive disorder, anxiety disorders, hallucinations in Parkinsons disease patients using ropinirole, and as a sedative for those with sleep disorders. The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; for the same reason, abuse of other antipsychotics, such as chlorpromazine (Thorazine), may occur as well, but research related to the abuse of typical antipsychotics is limited. for the same reason, abuse of other antipsychotics, such as chlorpromazine (Thorazine), may occur as well, but research related to the abuse of typical antipsychotics is limited. The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; Quetiapine belongs to a series of neuroleptics known as "atypical antipsychotics", which have become increasingly popular alternatives to "typical antipsychotics" such as haloperidol. N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AH - Diazepines, oxazepines, thiazepines and oxepines D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].

   

Deoxyaureothin

Deoxyaureothin

C22H25NO5 (383.173264)


A 4-pyranone that is 2-methoxy-3,5-dimethyl-4H-pyran-4-one which is substituted at position 6 by a 2,4-dimethyl-1-(p-nitrophenyl)hexa-1,3-dien-6-yl group (the E,E isomer).

   

Sacubitrilat

Sacubitrilat

C22H25NO5 (383.173264)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent

   

N-[(1R)-2,3-Dihydro-1H-inden-1-yl]-adenosine

2-{6-[(2,3-dihydro-1H-inden-1-yl)amino]-9H-purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol

C19H21N5O4 (383.15934660000005)


   

3-((2'-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine

4-({2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl}methyl)-[1,1-biphenyl]-2-carboxylic acid

C24H21N3O2 (383.1633686)


   

Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate

methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazol-3-yl}formamido)-3-methylbutanoate

C21H22FN3O3 (383.16451140000004)


   

Sacubitrilat

5-{[1,1-biphenyl]-4-yl}-4-[(3-carboxy-1-hydroxypropylidene)amino]-2-methylpentanoate

C22H25NO5 (383.173264)


   
   

Dehydrothalicsimidine

Dehydrothalicsimidine

C22H25NO5 (383.173264)


   

(+)-trans-Erioaustralasine

(+)-trans-Erioaustralasine

C22H25NO5 (383.173264)


   

N,N-Dimethyl-2-(1,2,3-trimethoxynaphtho(2,1-f)(1,3)benzodioxol-4-yl)ethanamine

N,N-Dimethyl-2-(1,2,3-trimethoxynaphtho(2,1-f)(1,3)benzodioxol-4-yl)ethanamine

C22H25NO5 (383.173264)


   

2-(2,3-Dimethoxyphenyl)-5,8-dimethoxy-3-propyl-4(1H)-quinolinone

2-(2,3-Dimethoxyphenyl)-5,8-dimethoxy-3-propyl-4(1H)-quinolinone

C22H25NO5 (383.173264)


   
   
   

3,4-dimethoxy-6,13-dimethyl-5,7,8,15-tetrahydro-6H-benzo[c][1,3]dioxolo[4,5:4,5]benzo[1,2-g]azecin-14-one

3,4-dimethoxy-6,13-dimethyl-5,7,8,15-tetrahydro-6H-benzo[c][1,3]dioxolo[4,5:4,5]benzo[1,2-g]azecin-14-one

C22H25NO5 (383.173264)


   
   

(+/-)-raddeanamine

(+/-)-raddeanamine

C22H25NO5 (383.173264)


   

6-[(Isopropyloxy)methyl]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one

6-[(Isopropyloxy)methyl]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one

C24H21N3O2 (383.1633686)


   

9H-Purin-6-amine, N-(3-methylbutyl)-2-(methylthio)-9-pentofuranosyl-

9H-Purin-6-amine, N-(3-methylbutyl)-2-(methylthio)-9-pentofuranosyl-

C16H25N5O4S (383.16271700000004)


   

(+/-)-Corycavidine

(+/-)-Corycavidine

C22H25NO5 (383.173264)


   

5,8-dimethoxy-2-(3,4-dimethoxyphenyl)-3-propyl-1h-quinolin-4-one

5,8-dimethoxy-2-(3,4-dimethoxyphenyl)-3-propyl-1h-quinolin-4-one

C22H25NO5 (383.173264)


   

(7Xi,8S)-8,6,7-trimethoxy-2-methyl-6,8,3,4-tetrahydro-2H-spiro[indeno[4,5-d][1,3]dioxole-7,1-isoquinoline]|Fumaritrin

(7Xi,8S)-8,6,7-trimethoxy-2-methyl-6,8,3,4-tetrahydro-2H-spiro[indeno[4,5-d][1,3]dioxole-7,1-isoquinoline]|Fumaritrin

C22H25NO5 (383.173264)


   
   

Me glycoside,N,4-O-dibenzoyl-beta-L-Pyranose-3-Amino-2,3,6-trideoxy-3-C-methyl-xylo-hexose

Me glycoside,N,4-O-dibenzoyl-beta-L-Pyranose-3-Amino-2,3,6-trideoxy-3-C-methyl-xylo-hexose

C22H25NO5 (383.173264)


   

N-[2-(7-Hydroxy-3,4,6-trimethoxyphenanthren-1-yl)ethyl]-N-methylacetamide

N-[2-(7-Hydroxy-3,4,6-trimethoxyphenanthren-1-yl)ethyl]-N-methylacetamide

C22H25NO5 (383.173264)


   
   

Me glycoside,N,4-dibenzoyl-alpha-L-Pyranose-3-Amino-2,3,6-trideoxy-3-C-methyl-xylo-hexose

Me glycoside,N,4-dibenzoyl-alpha-L-Pyranose-3-Amino-2,3,6-trideoxy-3-C-methyl-xylo-hexose

C22H25NO5 (383.173264)


   
   
   

Dehydrocorydaline (hydroxyl)

Dehydrocorydaline (hydroxyl)

C22H25NO5 (383.173264)


   

prazosin

prazosin

C19H21N5O4 (383.15934660000005)


C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS relative retention time with respect to 9-anthracene Carboxylic Acid is 0.767 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.759 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.760 Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder. It is an alpha-adrenergic blocker that is specific for the alpha-1 receptors. These receptors are found on vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine. They are also found throughout the central nervous system. As of 2013, prazosin is off-patent in the US, and the FDA has approved at least one generic manufacturer.In addition to its alpha-blocking activity, prazosin is an antagonist of the MT3 receptor (which is not present in humans), with selectivity for this receptor over the MT1 and MT2 receptors. Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. However, when prazosin is initially started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases.

   

(6aS)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-3-carbaldehyde

(6aS)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-3-carbaldehyde

C22H25NO5 (383.173264)


relative retention time with respect to 9-anthracene Carboxylic Acid is 0.778 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.773

   

6,7-Dimethoxy-1-[2-(2,3,4-trimethoxy-phenyl)-vinyl]-3,4-dihydro-isoquinoline

"NCGC00160170-01!6,7-Dimethoxy-1-[2-(2,3,4-trimethoxy-phenyl)-vinyl]-3,4-dihydro-isoquinoline"

C22H25NO5 (383.173264)


   

Peniprequinolone_120176

Peniprequinolone_120176

C22H25NO5 (383.173264)


   

C22H25NO5_(3R,4R)-4,5-Dihydroxy-3-methoxy-4-(4-methoxyphenyl)-6-(3-methyl-2-buten-1-yl)-3,4-dihydro-2(1H)-quinolinone

NCGC00169912-03_C22H25NO5_(3R,4R)-4,5-Dihydroxy-3-methoxy-4-(4-methoxyphenyl)-6-(3-methyl-2-buten-1-yl)-3,4-dihydro-2(1H)-quinolinone

C22H25NO5 (383.173264)


   

quetiapine

quetiapine

C21H25N3O2S (383.166739)


N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AH - Diazepines, oxazepines, thiazepines and oxepines D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].

   
   
   

N-Boc-4-[2-(4-Toluenesulfonyloxy)ethyl]piperidine

N-Boc-4-[2-(4-Toluenesulfonyloxy)ethyl]piperidine

C19H29NO5S (383.17663440000007)


   

PD 117519

PD 117519

C19H21N5O4 (383.15934660000005)


PD 117519 (CI947) is an A2A adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models[1][2]. PD 117519 (CI947) is an A2A adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models[1][2].

   

nalpha-fmoc-l-serine tert-butyl ester

nalpha-fmoc-l-serine tert-butyl ester

C22H25NO5 (383.173264)


   

3-Methyl-2-(tributylstannyl)pyridine

3-Methyl-2-(tributylstannyl)pyridine

C18H33NSn (383.1634848)


   

FMOC-(2S,3S)-3-AMINO-2-HYDROXY-5-METHYLHEXANOIC ACID

FMOC-(2S,3S)-3-AMINO-2-HYDROXY-5-METHYLHEXANOIC ACID

C22H25NO5 (383.173264)


   

5-Methyl-2-(tributylstannyl)pyridine

5-Methyl-2-(tributylstannyl)pyridine

C18H33NSn (383.1634848)


   

4-Methyl-2-(tributylstannyl)pyridine

4-Methyl-2-(tributylstannyl)pyridine

C18H33NSn (383.1634848)


   

2-Methyl-6-(tributylstannyl)pyridine

2-Methyl-6-(tributylstannyl)pyridine

C18H33NSn (383.1634848)


   
   

N-(1-(2-(1H-INDOL-3-YL)ETHYL)PIPERIDIN-4-YL)BENZAMIDE HYDROCHLORIDE

N-(1-(2-(1H-INDOL-3-YL)ETHYL)PIPERIDIN-4-YL)BENZAMIDE HYDROCHLORIDE

C22H26ClN3O (383.17642960000006)


   

(3,3,4,4,4-D5)-(E/Z)-1-[4-(2-CHLOROETHOXY)PHENYL]-1-[4-HYDROXYPHENYL]-2-PHENYL-1-BUTENE

(3,3,4,4,4-D5)-(E/Z)-1-[4-(2-CHLOROETHOXY)PHENYL]-1-[4-HYDROXYPHENYL]-2-PHENYL-1-BUTENE

C24H18ClD5O2 (383.17003468999997)


   

4-(trans-4-Propylcyclohexyl)benzoic acid 4-cyano-3,5-difluorophenyl ester

4-(trans-4-Propylcyclohexyl)benzoic acid 4-cyano-3,5-difluorophenyl ester

C23H23F2NO2 (383.16967619999997)


   

Fmoc-D-Ser(tBu)-OH

Fmoc-D-Ser(tBu)-OH

C22H25NO5 (383.173264)


   

3-((2-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine

3-((2-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine

C24H21N3O2 (383.1633686)


D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers

   

Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-DL-valinate

Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-DL-valinate

C21H22FN3O3 (383.16451140000004)


   

N-((1-(2-(tert-Butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide

N-((1-(2-(tert-Butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide

C19H27ClFN3O2 (383.1775724)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

(2s)-1-{[5-(1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-[(7as)-7ah-Indol-3-Yl]propan-2-Amine

(2s)-1-{[5-(1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-[(7as)-7ah-Indol-3-Yl]propan-2-Amine

C23H21N5O (383.1746016)


   

beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine

beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine

C14H27N2O10+ (383.1665622)


   

N-acetyl-beta-D-glucosaminyl-(1->4)-D-glucosaminium(1+)

N-acetyl-beta-D-glucosaminyl-(1->4)-D-glucosaminium(1+)

C14H27N2O10+ (383.1665622)


   

Torrubiellone D

Torrubiellone D

C22H25NO5 (383.173264)


A natural product found in Torrubiella species.

   

2-(3,5-Diphenyl-3,4-dihydropyrazol-2-yl)-2-(4-hydroxy-3-methoxyphenyl)acetonitrile

2-(3,5-Diphenyl-3,4-dihydropyrazol-2-yl)-2-(4-hydroxy-3-methoxyphenyl)acetonitrile

C24H21N3O2 (383.1633686)


   

3-(1-methyl-1H-pyrrol-2-yl)-N-[(E)-(2,4,5-trimethoxyphenyl)methylidene]-1H-pyrazole-5-carbohydrazide

3-(1-methyl-1H-pyrrol-2-yl)-N-[(E)-(2,4,5-trimethoxyphenyl)methylidene]-1H-pyrazole-5-carbohydrazide

C19H21N5O4 (383.15934660000005)


   

6,7-dimethoxy-1-[(E)-2-(2,3,4-trimethoxyphenyl)ethenyl]-3,4-dihydroisoquinoline

6,7-dimethoxy-1-[(E)-2-(2,3,4-trimethoxyphenyl)ethenyl]-3,4-dihydroisoquinoline

C22H25NO5 (383.173264)


   

6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine

6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine

C24H21N3O2 (383.1633686)


   

2-(3-isopropyloxyphenyl)-N-(pyridin-4-yl)quinoline-4-carboxamide

2-(3-isopropyloxyphenyl)-N-(pyridin-4-yl)quinoline-4-carboxamide

C24H21N3O2 (383.1633686)


   

5-(3,4-Dimethoxyphenyl)-2-methyl-4-(4-methyl-1-piperidinyl)thieno[2,3-d]pyrimidine

5-(3,4-Dimethoxyphenyl)-2-methyl-4-(4-methyl-1-piperidinyl)thieno[2,3-d]pyrimidine

C21H25N3O2S (383.166739)


   
   
   
   
   
   
   
   
   
   
   

(3-Acetyloxy-2-pentanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

(3-Acetyloxy-2-pentanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C15H30NO8P (383.17089500000003)


   

(2-Butanoyloxy-3-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

(2-Butanoyloxy-3-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C15H30NO8P (383.17089500000003)


   

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] hexanoate

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] hexanoate

C15H30NO8P (383.17089500000003)


   

[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] octanoate

[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] octanoate

C15H30NO8P (383.17089500000003)


   

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-pentanoyloxypropyl] pentanoate

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-pentanoyloxypropyl] pentanoate

C15H30NO8P (383.17089500000003)


   

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] heptanoate

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] heptanoate

C15H30NO8P (383.17089500000003)


   

PE(10:0)

PE(4:0_6:0)

C15H30NO8P (383.17089500000003)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

BAY1125976

BAY1125976

C23H21N5O (383.1746016)


BAY1125976 is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.

   

Dehydrocorydaline (hydroxyl)

Dehydrocorydaline (hydroxyl)

C22H25NO5 (383.173264)


Dehydrocorydaline (13-Methylpalmatine) hydroxyl is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline hydroxyl elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline hydroxyl shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90\%) using P. falciparum 3D7 strain.